Novo Nordisk Shares Surge 9.9% After Hims & Hers Halts $49 Wegovy Pill
Novo Nordisk ADR shares gained 9.92% after Hims & Hers halted its $49 compounded Wegovy pill service following legal threats over unauthorized mass-selling. The move follows scrutiny over Hims & Hers’ multi-cancer blood test, which detected roughly 40% of cancers in interim trials.
1. Hims & Hers Halts Compounded Wegovy Pill
Hims & Hers ceased offering its $49 compounded version of Novo Nordisk’s Wegovy weight-loss drug after receiving an FDA warning and facing legal threats from Novo Nordisk over unauthorized mass-selling of semaglutide.
2. Novo Nordisk Stock Reaction
Novo Nordisk ADR shares jumped 9.92% as investors anticipated reduced competition in the semaglutide market and viewed the halt as a validation of Novo Nordisk’s intellectual property enforcement.
3. Cancer Test Raises Operational Concerns
The decision coincided with scrutiny of Hims & Hers’ recent Super Bowl ad promoting Grail Inc.’s multi-cancer blood test, which detected about 40% of cancers in October 2025 interim data, fueling broader regulatory concerns.